Licensing With Inadequate Staff May Lead To Delay In Granting Product
Pharmaceutical companies in the country may have to cope with serious
delays in getting their applications for drug licenses cleared once
Central Drugs Authority (CDA) of India is formed. Such delays in the
initial phase of its existence are inevitable as the staff strength of
Central Drugs Control Organisation is highly inadequate to handle the
vast number of applications that may pour in from various states,
according to All India Drug Control Officers Association (AIDCOC).
Authority Will Be Formed In Six Months : Dr Ramadoss
The much awaited
Central Drugs Authority of India (CDA (I), stated to be formed in line
with the US FDA would be ready within six months from now. The meeting
was held to discuss relevant issues about the same and it was cleared
by the cabinet. The issue to set up the CDA (I) had been pending for
the last many years and the final decision to set it up had been taken
Picks Up Majority Stake In Taiwanese Dialysis Firm
Fresenius Medical Care AG & Co. KGaA
continues to expand in Asia. The company announced the acquisition of
a 51 per cent equity interest in Jiate Excelsior Co. Ltd. (Excelsior)
in Taiwan. With a market share of approximately 14 percent Excelsior
is the largest dialysis service provider in Taiwan treating over6,500
hemodialysis patients in 90 clinics.
Healthcare Segment May Replicate The Success Of The Indian IT Sector,
The corporatisation of the Indian hospital
sector has begun in a big way. Well known corporates such as Escorts
and Apollo are already in expansion mode.
IPR Comes With New Hi-tech Medical Waste Disposable Plan For Hospitals
Hospitals may soon be able to dispose off
medical wastes in an eco-friendly manner using a new technology.
Gandhinagar based Institute of Plasma Research (IPR) has developed a
new non-burn technology - plasma pyrolysis process - which will make
it possible to dispose off medical wastes without using traditional
methods of burning or dumping the same.
Expand Dialyzer Production Capacity At St Wandel
Fresenius Medical Care is expanding the
dialyzer production capacity at the St. Wandel (Germany) production
facility by 40 percent. A total of 36 million will be invested
including associated investment in additional production capacity for
proprietary Helixone Fibers.
Marck Biosciences In
Talks With US Cos For Site Transfer
Marck Biosciences is talking to several US
based pharma companies for a site transfer deal, through which it can
undertake contract manufacturing of small volume parenterals and
injectibles at its facility in Gujarat. Through this process, an US
based pharma company move its production of a particular molecule to
India by getting US FDA approval for Marck's production facility.
Ranbaxy Group Forays
Into Retail Healthcare
The Ranbaxy promoter group will mark its
foray into healthcare retail through a new company, Fortis Health
World, which plans to set up 1,000 HealthWorld store in 400 cities in
the next five years at an outlay of Rs. 800 crore.
Corona Cardiac Cathlab
Hospital visits can be harrowing
experiences, but thanks to Design Directions, this cardiac system is
not only full of mind boggling science, but it also offers impressive